Carole Bellis is a partner in the firm’s M&A and Securities group, based in Silicon Valley. Her practice is focused on the representation of startup and rapid growth companies with an emphasis on securities issuances, M&A transactions, intellectual property protection and licensing matters. She represents a large portfolio of technology companies in the biotech, medical device, software and energy sectors. She often serves as outside general counsel for her clients and regularly advises boards of directors and senior management on matters of corporate governance, preferred stock and debt financings, executive compensation and employment matters, commercial transactions, joint ventures and strategic transactions. She also represents investors and investment funds. Her M&A experience includes domestic and cross-border transactions, stock and asset based transactions, spin-off’s and going private transactions ranging in value from several million to several billion dollars.

Before attending law school, Carole was an executive in a government relations firm representing major corporations, foreign governments, professional and trade associations before the California state legislature. She began her legal career in Paris in 1997 and has been practicing in Silicon Valley since 1999.

Education

  • University of San Francisco School of Law, J.D.
  • Florida State University, B.S., Business Administration

Bar Admissions

  • California (1997)

Who We Are

1080 Marsh Road
Menlo Park, CA, 94025
USA
t +1 650.462.5313
f +1 650.644.0477
9720 Wilshire Blvd PH
Beverly Hills, CA, 90212-2018
USA
t +1 310.777.3724

Carole H. Bellis

Experience Highlights

$43M financing for Editas Medicine, Inc.
Represented the founders of Editas Medicine, Incorporated in a $43 million Series A Financing to fund the collaborative research and more
$40 million Series C Financing for Investors
Represent lead investors in $40 million Series C Financing of Hyperfine Research, Inc. more
Series Seed Financing for Infinite Uptime
Represent Infinite Uptime in Series Seed Financing by Mayfield. more
$12M financing for MVRx
Represented MVRx, a medical device technology company, in $12 million Series A financing by a strategic investor. more